Spots Global Cancer Trial Database for AMG 404 in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: AMG 404 in Patients With Advanced Solid Tumors
Official Title: A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients With Advanced Solid Tumors
Study ID: NCT03853109
Conditions
Interventions
Study Description
Brief Summary: To evaluate the safety and tolerability of AMG 404, a monoclonal antibody that binds to PD-1 and inhibits its engagement with ligands, in patients with advanced solid tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sarcoma Oncology Research Center LLC, Santa Monica, California, United States
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, United States
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Chris OBrien Lifehouse, Camperdown, New South Wales, Australia
The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
Universitair Ziekenhuis Antwerpen, Edegem, , Belgium
Nucleo de Oncologia da Bahia, Salvador, Bahia, Brazil
Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, Brazil
Sociedade Beneficente de Senhoras Hospital Sirio Libanes, Sao Paulo, São Paulo, Brazil
Hospital de Base de Sao Jose do Rio Preto, São José do Rio Preto, São Paulo, Brazil
Instituto Coi, Rio de Janeiro, , Brazil
Tom Baker Cancer Centre, Calgary, Alberta, Canada
National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
National Hospital Organization Shikoku Cancer Center, Matsuyama-shi, Ehime, Japan
Wakayama Medical University Hospital, Wakayama-shi, Wakayama, Japan
Seoul National University Hospital, Seoul, , Korea, Republic of
Severance Hospital Yonsei University Health System, Seoul, , Korea, Republic of
Asan Medical Center, Seoul, , Korea, Republic of
Samsung Medical Center, Seoul, , Korea, Republic of
The Catholic University of Korea Seoul St Marys Hospital, Seoul, , Korea, Republic of
Uniwersyteckie Centrum Kliniczne, Gdansk, , Poland
Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Warszawa, , Poland
National University Hospital, Singapore, , Singapore
National Cancer Centre Singapore, Singapore, , Singapore
Hospital Universitari Vall d Hebron, Barcelona, Cataluña, Spain
Hospital Universitario La Paz, Madrid, , Spain
Taipei Veterans General Hospital, Taipei, , Taiwan
Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan, , Taiwan
Doktor Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi, Ankara, , Turkey
Koc Universitesi Hastanesi, Istanbul, , Turkey
Ege Universitesi Ilac Gelistirme ve Farmakokinetik Arastirma Uygulama Merkezi (ARGEFAR), Izmir, , Turkey
Sarah Cannon Research Institute UK, London, , United Kingdom
Contact Details
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
